PuraMatrixTM Facilitates Bone Regeneration in Bone Defects of Calvaria in Mice
Abstract:Artificial bones have often used for bone regeneration due to their strength, but they cannot provide an adequate environment for cell penetration and settlement. We therefore attempted to explore various materials that may allow the cells to penetrate and engraft in bone defects. PuraMatrixTM is a self-assembling peptide scaffold that produces a nanoscale environment allowing both cellular penetration and engraftment. The objective of this study was to investigate the effect of PuraMatrixTM on bone regeneration in a mouse bone defect model of the calvaria. MatrigelTM was used as a control. The expression of bone-related genes (alkaline phosphatase, Runx2, and Osterix) in the PuraMatrixTM-injected bone defects was stronger than that in the MatrigelTM-injected defects. Soft X-ray radiographs revealed that bony bridges were clearly observed in the defects treated with PuraMatrixTM, but not in the MatrigelTM-treated defects. Notably, PuraMatrixTM treatment induced mature bone tissue while showing cortical bone medullary cavities. The area of newly formed bones at the site of the bone defects was 1.38-fold larger for PuraMatrixTM than MatrigelTM. The strength of the regenerated bone was 1.72-fold higher for PuraMatrixTM (146.0 g) than for MatrigelTM (84.7 g). The present study demonstrated that PuraMatrixTM injection favorably induced functional bone regeneration.
Document Type: Research Article
Affiliations: 1: Department of Orthopeadic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan 2: Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan 3: 3-DMatrix Japan, Ltd., Tokyo 102-0083, Japan 4: Dainippon Sumitomo Pharma. Co. Ltd., Osaka 541-0045, Japan
Publication date: October 1, 2006
- Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.